Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function.

American journal of clinical and experimental immunology

Noonan T, Lukas S, Peet GW, Pelletier J, Panzenbeck M, Hanidu A, Mazurek S, Wasti R, Rybina I, Roma T, Kronkaitis A, Shoultz A, Souza D, Jiang H, Nabozny G, Modis LK.
PMID: 23885334
Am J Clin Exp Immunol. 2013 Jun 15;2(2):172-85. Print 2013.

Vascular adhesion protein-1 (VAP-1) has been implicated in the pathogenesis of inflammatory diseases and is suggested to play a role in immune cell trafficking. It is not clear whether this effect is mediated by the oxidase activity or by...

Cite
Noonan T, Lukas S, Peet GW, et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am J Clin Exp Immunol. 2013;2(2):172-85
Noonan, T., Lukas, S., Peet, G. W., Pelletier, J., Panzenbeck, M., Hanidu, A., Mazurek, S., Wasti, R., Rybina, I., Roma, T., Kronkaitis, A., Shoultz, A., Souza, D., Jiang, H., Nabozny, G., & Modis, L. K. (2013). The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. American journal of clinical and experimental immunology, 2(2), 172-85.
Noonan, Thomas, et al. "The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function." American journal of clinical and experimental immunology vol. 2,2 (2013): 172-85.
Noonan T, Lukas S, Peet GW, Pelletier J, Panzenbeck M, Hanidu A, Mazurek S, Wasti R, Rybina I, Roma T, Kronkaitis A, Shoultz A, Souza D, Jiang H, Nabozny G, Modis LK. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am J Clin Exp Immunol. 2013 Jun 15;2(2):172-85. Print 2013. PMID: 23885334; PMCID: PMC3714173.
Copy Download .nbib Format: NLM
Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357.

ACS medicinal chemistry letters

Harcken C, Csengery J, Turner M, Wu L, Liang S, Sibley R, Brunette S, Labadia M, Hoyt K, Wayne A, Wieckowski T, Davis G, Panzenbeck M, Souza D, Kugler S, Terenzio D, Collin D, Smith D, Fryer RM, Tseng YC, Hehn JP, Fletcher K, Hughes RO.
PMID: 33488976
ACS Med Chem Lett. 2021 Jan 05;12(1):143-154. doi: 10.1021/acsmedchemlett.0c00575. eCollection 2021 Jan 14.

The interleukin (IL)-23/T helper (Th)17 axis plays a critical role in autoimmune diseases, and there is an increasing number of biologic therapies that target IL-23 and IL-17. The transcription factor retinoic acid receptor-related orphan nuclear receptor γt (RORγt) is...

Cite
Harcken C, Csengery J, Turner M, et al. Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357. ACS Med Chem Lett. 2021;12(1):143-154doi: 10.1021/acsmedchemlett.0c00575.
Harcken, C., Csengery, J., Turner, M., Wu, L., Liang, S., Sibley, R., Brunette, S., Labadia, M., Hoyt, K., Wayne, A., Wieckowski, T., Davis, G., Panzenbeck, M., Souza, D., Kugler, S., Terenzio, D., Collin, D., Smith, D., Fryer, R. M., Tseng, Y. C., Hehn, J. P., Fletcher, K., & Hughes, R. O. (2021). Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357. ACS medicinal chemistry letters, 12(1), 143-154. https://doi.org/10.1021/acsmedchemlett.0c00575
Harcken, Christian, et al. "Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357." ACS medicinal chemistry letters vol. 12,1 (2021): 143-154. doi: https://doi.org/10.1021/acsmedchemlett.0c00575
Harcken C, Csengery J, Turner M, Wu L, Liang S, Sibley R, Brunette S, Labadia M, Hoyt K, Wayne A, Wieckowski T, Davis G, Panzenbeck M, Souza D, Kugler S, Terenzio D, Collin D, Smith D, Fryer RM, Tseng YC, Hehn JP, Fletcher K, Hughes RO. Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357. ACS Med Chem Lett. 2021 Jan 05;12(1):143-154. doi: 10.1021/acsmedchemlett.0c00575. eCollection 2021 Jan 14. PMID: 33488976; PMCID: PMC7812678.
Copy Download .nbib Format: NLM
Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers.

Crohn's & colitis 360

Wohnhaas CT, Schmid R, Rolser M, Kaaru E, Langgartner D, Rieber K, Strobel B, Eisele C, Wiech F, Jakob I, Gantner F, Herichova I, Vinisko R, Böcher WO, Visvanathan S, Shen F, Panzenbeck M, Raymond E, Reber SO, Delić D, Baum P.
PMID: 32551441
Crohns Colitis 360. 2020 Jan;2(1):otaa003. doi: 10.1093/crocol/otaa003. Epub 2020 Feb 14.

BACKGROUND: Short non-coding microRNAs (miRNAs) are involved in various cellular processes during disease progression of Crohn's disease (CD) and remarkably stable in feces, which make them attractive biomarker candidates for reflecting intestinal inflammatory processes. Here we investigated the potential...

Cite
Wohnhaas CT, Schmid R, Rolser M, et al. Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers. Crohns Colitis 360. 2020;2(1):otaa003doi: 10.1093/crocol/otaa003.
Wohnhaas, C. T., Schmid, R., Rolser, M., Kaaru, E., Langgartner, D., Rieber, K., Strobel, B., Eisele, C., Wiech, F., Jakob, I., Gantner, F., Herichova, I., Vinisko, R., Böcher, W. O., Visvanathan, S., Shen, F., Panzenbeck, M., Raymond, E., Reber, S. O., Delić, D., & Baum, P. (2020). Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers. Crohn's & colitis 360, 2(1), otaa003. https://doi.org/10.1093/crocol/otaa003
Wohnhaas, Christian T, et al. "Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers." Crohn's & colitis 360 vol. 2,1 (2020): otaa003. doi: https://doi.org/10.1093/crocol/otaa003
Wohnhaas CT, Schmid R, Rolser M, Kaaru E, Langgartner D, Rieber K, Strobel B, Eisele C, Wiech F, Jakob I, Gantner F, Herichova I, Vinisko R, Böcher WO, Visvanathan S, Shen F, Panzenbeck M, Raymond E, Reber SO, Delić D, Baum P. Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers. Crohns Colitis 360. 2020 Jan;2(1):otaa003. doi: 10.1093/crocol/otaa003. Epub 2020 Feb 14. PMID: 32551441; PMCID: PMC7291945.
Copy Download .nbib Format: NLM
Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357.

ACS medicinal chemistry letters

Harcken C, Csengery J, Turner M, Wu L, Liang S, Sibley R, Brunette S, Labadia M, Hoyt K, Wayne A, Wieckowski T, Davis G, Panzenbeck M, Souza D, Kugler S, Terenzio D, Collin D, Smith D, Fryer RM, Tseng YC, Hehn JP, Fletcher K, Hughes RO.
PMID: 33488976
ACS Med Chem Lett. 2021 Jan 05;12(1):143-154. doi: 10.1021/acsmedchemlett.0c00575. eCollection 2021 Jan 14.

The interleukin (IL)-23/T helper (Th)17 axis plays a critical role in autoimmune diseases, and there is an increasing number of biologic therapies that target IL-23 and IL-17. The transcription factor retinoic acid receptor-related orphan nuclear receptor γt (RORγt) is...

Cite
Harcken C, Csengery J, Turner M, et al. Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357. ACS Med Chem Lett. 2021;12(1):143-154doi: 10.1021/acsmedchemlett.0c00575.
Harcken, C., Csengery, J., Turner, M., Wu, L., Liang, S., Sibley, R., Brunette, S., Labadia, M., Hoyt, K., Wayne, A., Wieckowski, T., Davis, G., Panzenbeck, M., Souza, D., Kugler, S., Terenzio, D., Collin, D., Smith, D., Fryer, R. M., Tseng, Y. C., Hehn, J. P., Fletcher, K., & Hughes, R. O. (2021). Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357. ACS medicinal chemistry letters, 12(1), 143-154. https://doi.org/10.1021/acsmedchemlett.0c00575
Harcken, Christian, et al. "Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357." ACS medicinal chemistry letters vol. 12,1 (2021): 143-154. doi: https://doi.org/10.1021/acsmedchemlett.0c00575
Harcken C, Csengery J, Turner M, Wu L, Liang S, Sibley R, Brunette S, Labadia M, Hoyt K, Wayne A, Wieckowski T, Davis G, Panzenbeck M, Souza D, Kugler S, Terenzio D, Collin D, Smith D, Fryer RM, Tseng YC, Hehn JP, Fletcher K, Hughes RO. Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357. ACS Med Chem Lett. 2021 Jan 05;12(1):143-154. doi: 10.1021/acsmedchemlett.0c00575. eCollection 2021 Jan 14. PMID: 33488976; PMCID: PMC7812678.
Copy Download .nbib Format: NLM
Trigger Site Deactivation Surgery for Headaches is Associated with Decreased Postoperative Medication Use.

Plastic and reconstructive surgery. Global open

Ortiz R, Gfrerer L, Panzenbeck P, Hansdorfer MA, Austen WG.
PMID: 34150427
Plast Reconstr Surg Glob Open. 2021 Jun 15;9(6):e3634. doi: 10.1097/GOX.0000000000003634. eCollection 2021 Jun.

Patients with chronic headaches suffer debilitating pain, which often leads to the use of numerous medications. Trigger site deactivation surgery has emerged as an effective treatment for select headache patients. This study aims to describe the preoperative and postoperative...

Cite
Ortiz R, Gfrerer L, Panzenbeck P, et al. Trigger Site Deactivation Surgery for Headaches is Associated with Decreased Postoperative Medication Use. Plast Reconstr Surg Glob Open. 2021;9(6):e3634doi: 10.1097/GOX.0000000000003634.
Ortiz, R., Gfrerer, L., Panzenbeck, P., Hansdorfer, M. A., & Austen, W. G. (2021). Trigger Site Deactivation Surgery for Headaches is Associated with Decreased Postoperative Medication Use. Plastic and reconstructive surgery. Global open, 9(6), e3634. https://doi.org/10.1097/GOX.0000000000003634
Ortiz, Ricardo, et al. "Trigger Site Deactivation Surgery for Headaches is Associated with Decreased Postoperative Medication Use." Plastic and reconstructive surgery. Global open vol. 9,6 (2021): e3634. doi: https://doi.org/10.1097/GOX.0000000000003634
Ortiz R, Gfrerer L, Panzenbeck P, Hansdorfer MA, Austen WG. Trigger Site Deactivation Surgery for Headaches is Associated with Decreased Postoperative Medication Use. Plast Reconstr Surg Glob Open. 2021 Jun 15;9(6):e3634. doi: 10.1097/GOX.0000000000003634. eCollection 2021 Jun. PMID: 34150427; PMCID: PMC8205194.
Copy Download .nbib Format: NLM
Indole Inhibitors of MMP-13 for Arthritic Disorders.

ACS omega

Taylor SJ, Abeywardane A, Liang S, Xiong Z, Proudfoot JR, Farmer BS, Gao DA, Heim-Riether A, Smith-Keenan LL, Muegge I, Yu Y, Zhang Q, Souza D, Panzenbeck M, Goldberg D, Hill-Drzewi M, Margarit M, Collins B, Li JX, Zuvela-Jelaska L, Li J, Farrow NA.
PMID: 34337203
ACS Omega. 2021 Jul 19;6(29):18635-18650. doi: 10.1021/acsomega.1c01320. eCollection 2021 Jul 27.

Here, we described the design, by fragment merging and multiparameter optimization, of selective MMP-13 inhibitors that display an appropriate balance of potency and physicochemical properties to qualify as tool compounds suitable for

Cite
Taylor SJ, Abeywardane A, Liang S, et al. Indole Inhibitors of MMP-13 for Arthritic Disorders. ACS Omega. 2021;6(29):18635-18650doi: 10.1021/acsomega.1c01320.
Taylor, S. J., Abeywardane, A., Liang, S., Xiong, Z., Proudfoot, J. R., Farmer, B. S., Gao, D. A., Heim-Riether, A., Smith-Keenan, L. L., Muegge, I., Yu, Y., Zhang, Q., Souza, D., Panzenbeck, M., Goldberg, D., Hill-Drzewi, M., Margarit, M., Collins, B., Li, J. X., Zuvela-Jelaska, L., Li, J., & Farrow, N. A. (2021). Indole Inhibitors of MMP-13 for Arthritic Disorders. ACS omega, 6(29), 18635-18650. https://doi.org/10.1021/acsomega.1c01320
Taylor, Steven J, et al. "Indole Inhibitors of MMP-13 for Arthritic Disorders." ACS omega vol. 6,29 (2021): 18635-18650. doi: https://doi.org/10.1021/acsomega.1c01320
Taylor SJ, Abeywardane A, Liang S, Xiong Z, Proudfoot JR, Farmer BS, Gao DA, Heim-Riether A, Smith-Keenan LL, Muegge I, Yu Y, Zhang Q, Souza D, Panzenbeck M, Goldberg D, Hill-Drzewi M, Margarit M, Collins B, Li JX, Zuvela-Jelaska L, Li J, Farrow NA. Indole Inhibitors of MMP-13 for Arthritic Disorders. ACS Omega. 2021 Jul 19;6(29):18635-18650. doi: 10.1021/acsomega.1c01320. eCollection 2021 Jul 27. PMID: 34337203; PMCID: PMC8319936.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries